Patent Expiry
TBPH: YUPELRI: recorded patent 11484531 expiry
October 23, 2039 · REVEFENACIN. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- October 23, 2039
- Company
- Theravance Biopharma, Inc. (TBPH)
- Drug
- REVEFENACIN
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Patent Expiry
YUPELRI: recorded patent 11484531 expiry
Orange Book application NDA210598, product 001, listed patent 11484531 expiry. Overall loss of exclusivity and current company rights: unknown.FDA source
- Drug
- REVEFENACIN